PARP inhibitors in ovarian cancer: Mechanisms, resistance, and the promise of combination therapy

被引：6

作者：

Bhatia, Tejas ^{[1
]}

Doshi, Gaurav ^{[1
]}

Godad, Angel ^{[1
]}

机构：

[1] SVKMs Dr Bhanuben Nanavati Coll Pharm, Dept Pharmacol, VLM Rd,Mithibai Campus,,Vile Parle West, Mumbai 400056, Maharashtra, India

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2024年 / 263卷

关键词：

Cancer; Poly ADP-ribose polymerase; PARP inhibitors; Ovarian cancer; Mutations; MUTATIONS; REPAIR;

D O I：

10.1016/j.prp.2024.155617

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Current approaches to treating ovarian cancer focus mainly on surgical cytoreduction and chemotherapy using platinum-based drugs, while newer methods such as immunotherapy are being investigated to enhance treatment outcomes. Treating ovarian cancer is complicated by challenges such as late-stage detection, tumor diversity, and limited treatment choices. Therefore, innovative strategies such as precision medicine and targeted therapies like PARPi (Poly ADP-Ribose Polymerase inhibitors) are increasingly necessary. The article highlights the significance of an innovative therapeutic approach focusing on PARPi in revolutionizing ovarian cancer treatment and improving patient outcomes. It covers the basic knowledge of PARP, its structure, and its function in DNA repair. It further emphasizes how inhibiting PARP can help in treating ovarian cancer. It elaborates on the mechanism of action of PARPi. It covers the clinical trials governing PARPi and the combination of drugs used with PARPi. It mentions how the resistance is developed to PARPi and the strategies to overcome the resistance developed.

引用

页数：12

共 112 条

[11]

[Anonymous], Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK- 3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer

[12]

[Anonymous], 2020, A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma, DOI 10.1097/MD9.0000000000000197

[13]

[Anonymous], Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

[14]

[Anonymous], 2023, Health Oncol. Hematol.., DOI [10.36000/HBT.OH.2023.18.128, DOI 10.36000/HBT.OH.2023.18.128]

[15]

[Anonymous], Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)

[16]

[Anonymous], Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas

[17]

[Anonymous], 2023, Univ. Technol.., DOI [10.5204/thesis.eprints.239785, DOI 10.5204/THESIS.EPRINTS.239785]

[18]

ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL), A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

[19]

ATHENA, A Multicenter, Randomized, Double-Blind, PlaceboControlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

[20] Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives [J].

Awada, Ahmad ;

Ahmad, Sarfraz ;

McKenzie, Nathalie D. ;

Holloway, Robert W. .

ONCOTARGETS AND THERAPY, 2022, 15 :853-866

← 1 2 3 4 5 6 7 8 9 10 →